Navigation Links
Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations
Date:10/28/2010


.33Shares used to compute net (loss) income per share (1):Basic58,13856,04557,47355,787Diluted66,61257,36866,21657,135(1) The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding of 323,582 and 638,105 for thethree months ended October 2, 2010 and October 3, 2009, respectively, and 386,808 and 724,469 for the nine monthsended October 2, 2010 and October 3, 2010, respectively.The following table reconciles the specific items excluded from GAAP net income from continuing operations in the calculation of non-GAAP net income from continuing operations and diluted net income per share from continuing operations for the periods shown below:

THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Net Income from Continuing Operations
(Unaudited)
(in thousands, except for per share data) Three Months Ended Nine Months Ended Net income reconciliationOctober 2,
2010October 3,
2009October 2,
2010October 3,
2009Net income from continuing operations on a GAAP basis$
5,480$
,776$
46,381$
20,832Share-based compensation expense:- Cost of product sales322234947789- Selling, general and administrative1,8581,6096,0745,153- Research and development7915942,6021,992Amortization of purchased intangibles2,4462,3597,3267,441HeartWare transaction costs-984-12,314Impact of ASC 470-202,1291,9456,1685,659Unrealized gain on embedded derivative
instrument on HeartWare loan-(5,240)-(5,240)Income tax effect of non-GAAP income
before tax607(158)434(1,801)Income tax effect of non-GAAP
adjustments(2,820)(832)(8,236)(8,785)Net income from continuing operations on a non-GAAP basis$
20,813$
3,271$
,696$
38,354 Three Months Ended Nine Months Ended Diluted net income from continuing operations per share reconciliationOctober 2,
2010October 3,
2009October 2,
2010October 3,
2009Di
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... July 30, 2014 Everyone knows that the ... basically everyone. Whether people are looking for something to buy, ... a dentist, the internet is pretty much always going to ... Dental in Lauderdale Florida is so happy to announce the ... web presence into the modern age. Whether a person wants ...
(Date:7/30/2014)... Dallas, Texas (PRWEB) July 30, 2014 ... provides key market data on the North America Contrast ... of US dollars, and volume (in units) and average ...     CT Injectors ,     Interventional Cardiology/Angio Injectors ... medium (or contrast agent) is a substance used to ...
(Date:7/30/2014)... (WAVES) conference is coming to Fairfield, Iowa,s Maharishi University ... August 3. To watch the main plenary talks, visit ... such a large and diverse group of Vedic scholars ... relevance of ancient Vedic knowledge in today,s world. Topics ... and reflections on the various Vedic texts. , The ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis Gilroy, ... of the American Telemedicine Association (ATA). The ... a mission to promote professional, ethical and equitable ... technology. , “Both Naomi Fried and Alexis Gilroy, ... and are well known experts in their respective ...
Breaking Medicine News(10 mins):Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2
... The Justice Department,today announced that it has reached ... is headquartered in Southfield, Mich., under the,Americans with ... Weight,Loss Clinic refused to serve a prospective client ... of today,s agreement, Medical Weight Loss Clinic will,provide ...
... to announce the arrival of newly FDA-approved Evolence®--the latest injectable ... beauty treatments. EVOLENCE® utilizes highly-purified porcine Type I collagen, regarded ... identical similarity to human collagen. , ... ...
... G.,Rendell today issued an executive order regarding the ... after the law,authorizing its operation expired on June ... when PHC4 was allowed to "sunset",by the General ... The Rendell administration is committed to creating ...
... serve a distinct advantage on, the road to recovery, said Carl ... ... July 8 The Mariners Inn shelter and treatment,center in downtown Detroit is ... chief operating officer., "Both Jim and David are outstanding leaders in the ...
... Reductions in Iron Blood Levels Associated with Decreased Cancer Risk ... peripheral arterial disease who participated in a randomized controlled trial ... had a reduced incidence of cancer relative to men in ... studies have suggested that lower levels of iron in the ...
... Act yet to show drop-off in access predicted by ... patients have not lost access to care despite federal ... recent years, a new report finds. , Critics feared ... would make treatment more difficult, but investigators from the ...
Cached Medicine News:Health News:Justice Department Reaches Settlement Agreement With Medical Weight Loss Clinic 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 2Health News:Move Over, Popular Beauty Fillers--Here Comes Evolence 3Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Mariners Inn Announces New Executive Leadership 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Affinity pacemaker ... today's smallest, truly automatic ... effective combination of advanced ... Affinity DR pacemaker incorporates ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... The Guidant INSIGNIA Ultra ... patient-specific, easy-to-use features for ... enhanced patient safety. All ... programmed using the ZOOM ...
Medicine Products: